Ray continued, “We’re also delighted to recognize Martin and Greg’s contributions to Synthekine with their new roles. Martin’s deep insights into cytokine biology and immunology were being instrumental to shaping the development of STK-012, our initial-in-course alpha/beta biased IL-2. Its distinctive system expands the therapeutic index of IL-2, one of https://https-www-zosanopharma-co21997.ampblogs.com/indicators-on-https-www-zosanopharma-com-technology-you-should-know-73352044